---
title: Evaluate long term gene therapy
nct_id: NCT07629115
status: RECRUITING
sponsor: Innopeutics Corporation
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07629115"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07629115"
last_fetched: "2026-07-02T14:04:52.502Z"
source: "Parkinson's Pathways (curated)"
---
# Evaluate long term gene therapy

**Goal (in five words):** Evaluate long term gene therapy

**Official Title:** A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial

**Trial ID:** [NCT07629115](https://clinicaltrials.gov/study/NCT07629115)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Innopeutics Corporation
- **Target Enrollment:** 6 participants
- **Start Date:** 2026-05-29
- **Completion Date:** 2031-07-30
- **Conditions:** Parkinson Disease, Parkinson's Disease

## Summary For Families

Goal: To check the long-term safety of IPS101A and to see whether any benefits people experienced after getting the gene therapy last over time. Approach: The study follows people who took part in the earlier IPS101A-10 trial and received the IPS101A gene therapy, with scheduled visits to monitor health and the durability of any effects. Eligibility: The study plans to include six people ages 50 to 80 who were in that earlier trial and received IPS101A, who can give written consent or have a family member or legal representative consent for them; people who decline, cannot complete follow up, or who have died are not included.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria

* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.
* Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.

Exclusion Criteria

* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.
* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.
```

## Locations (1)

- Severance Hospital, Seoul, South Korea _(37.5660, 126.9784)_
  - Professor, MD, PhD, (CONTACT), phlee@yuhs.ac

## Central Contacts

- ChoLong Park, (CONTACT), +82-2-3499-4266, clpark@innopeutics.com
- Tae-gyun Kim, (CONTACT), contact@innopeutics.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07629115*  
*HTML version: https://parkinsonspathways.com/trial/NCT07629115*  
*Source data: https://clinicaltrials.gov/study/NCT07629115*